Intratumoral Injection of Autologous CD1c (BDCA-1)+ Myeloid Dendritic Cells Plus Talimogene Laherparepvec (T-VEC)
NCT03747744
·
clinicaltrials.gov ↗
PHASE1
Phase
UNKNOWN
Status
18
Enrollment
OTHER
Sponsor class
Conditions
Melanoma
Interventions
OTHER:
CD1c (BDCA-1)+ myDC
Sponsor
Universitair Ziekenhuis Brussel